Fig. 3: Subgroup analyses of the Overall survival and Event free survival Study level characteristics.

The survival data from the pooled studies were used to estimate (A) the OS (right) and EFS (left) based on the co-stimulatory domain used in the study, (B) the OS (right) and EFS (left) based on the age range of the study population, (C) the OS (right) and EFS (left) based on the pretreatment disease status, (D) the OS (right) and EFS (left) stratified based on the dose of cyclophosphamide lymphodepletion, and (E) the OS (right) and EFS (left) based on the study type.